Canopy Growth Corp vs Health Care Select Sector SPDR Fund — how do they compare? Canopy Growth Corp trades at $0.96 (market cap $398.46M), while Health Care Select Sector SPDR Fund trades at $157.58. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | XLV | |
|---|---|---|
Market Cap | $398.46M | — |
Sector | Health | — |
52-Week High | $1.92 | $164.48 |
52-Week Low | $0.86 | $129.01 |
Enterprise Value | $337.90M | — |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
XLV trades at $161.41, up 0.35% with a bullish technical signal from moving averages. The healthcare ETF benefits from State Street's upgraded sector outlook and strong performance from holdings like Johnson & Johnson. Technical indicators show the price near pivot point resistance at $162 with ADX signaling strong trend momentum.
Healthcare sector rotation provides tailwinds as investors seek defensive exposure amid tech volatility. Key risks include patent cliffs and regulatory uncertainty, but diversified healthcare exposure offers stability with upcoming dividend distribution in June 2026 supporting total return potential.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →